Objective：The aim of this study was to analyze the clinical characteristics，treatment response and outcomes of follicular lymphoma（FL）grade 3A and grade 3B. Methods：Data of 51 patients，diagnosed as FL grade 3，were collected. Statistical analysis was performed to analyse the differences in clinical characteristics and outcomes. Results：Out of 51 FL3 cases，including FL3A in 34 cases（67%）and FL3B in 17 cases（33%），20 cases had diffuse large B cell lymphoma（DLBCL）component. The percentage of FL3B patients with DLBCL component was significantly higher than that of FL3A patients. Correlation analyses showed that FL3A was significantly associated with BCL2 positive expression（P=0.046），whereas FL3B was significantly associated with MUM1 positive expression（P=0.002）and early Ann-Abor staging（P=0.046）. All patients received first-line immunochemotherapy includes rituximab and chemotherapy. There was no significant difference between the two groups in response to treatment. Survival analyses showed that FL3B was an independent risk factor for progression free survival（PFS）in FL3 patients（P=0.048，HR=3.271，95% CI：1.012~10.573）. However，there was no significant difference between the two groups in terms of overall survival（OS）. FL3 co-existence with DLBCL component predicted shorter PFS（P=0.003）and OS（P=0.04）. The co-existence of DLBCL component was an independent prognostic factor for PFS and OS in FL3 patients（PFS：P=0.012，HR=4.291，95% CI：1.373~13.405；OS：P=0.013，HR=2.392，95% CI：1.199~4.771）. Conclusion：FL3A and FL3B had significant differences in clinical characteristics and outcomes. FL3B patients had shorter PFS. Moreover，FL3 coexistence with DLBCL component suggested poor prognosis.